HRP20210903T1 - Miješane formulacije - Google Patents
Miješane formulacije Download PDFInfo
- Publication number
- HRP20210903T1 HRP20210903T1 HRP20210903TT HRP20210903T HRP20210903T1 HR P20210903 T1 HRP20210903 T1 HR P20210903T1 HR P20210903T T HRP20210903T T HR P20210903TT HR P20210903 T HRP20210903 T HR P20210903T HR P20210903 T1 HRP20210903 T1 HR P20210903T1
- Authority
- HR
- Croatia
- Prior art keywords
- skin
- aoi
- formulation
- formulation according
- appearance
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title claims 25
- 239000000203 mixture Substances 0.000 title claims 25
- 239000002245 particle Substances 0.000 claims 10
- 238000001246 colloidal dispersion Methods 0.000 claims 8
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 8
- 239000004094 surface-active agent Substances 0.000 claims 7
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 6
- 150000002632 lipids Chemical group 0.000 claims 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 229960004889 salicylic acid Drugs 0.000 claims 4
- 235000010384 tocopherol Nutrition 0.000 claims 4
- 229960001295 tocopherol Drugs 0.000 claims 4
- 229930003799 tocopherol Natural products 0.000 claims 4
- 239000011732 tocopherol Substances 0.000 claims 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 4
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 3
- 206010000496 acne Diseases 0.000 claims 3
- 229960001948 caffeine Drugs 0.000 claims 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 3
- 229960003260 chlorhexidine Drugs 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 2
- 235000010323 ascorbic acid Nutrition 0.000 claims 2
- 239000011668 ascorbic acid Substances 0.000 claims 2
- 208000013715 atelosteogenesis type I Diseases 0.000 claims 2
- 229960002504 capsaicin Drugs 0.000 claims 2
- 235000017663 capsaicin Nutrition 0.000 claims 2
- 239000002537 cosmetic Substances 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000036548 skin texture Effects 0.000 claims 2
- 230000037303 wrinkles Effects 0.000 claims 2
- 239000011701 zinc Substances 0.000 claims 2
- 229910052725 zinc Inorganic materials 0.000 claims 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010013786 Dry skin Diseases 0.000 claims 1
- 206010014970 Ephelides Diseases 0.000 claims 1
- 208000003351 Melanosis Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229940072107 ascorbate Drugs 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 230000037336 dry skin Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 210000000744 eyelid Anatomy 0.000 claims 1
- 208000000069 hyperpigmentation Diseases 0.000 claims 1
- 230000003810 hyperpigmentation Effects 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 229910017053 inorganic salt Inorganic materials 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 229920002521 macromolecule Polymers 0.000 claims 1
- 229940041616 menthol Drugs 0.000 claims 1
- 239000011785 micronutrient Substances 0.000 claims 1
- 235000013369 micronutrients Nutrition 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000037394 skin elasticity Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Birds (AREA)
- Biochemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (15)
1. Formulacija koja sadrži prvu koloidnu disperziju i drugu koloidnu disperziju,
pri čemu svaka koloidna disperzija sadrži deformabilne koloidne čestice koje sadrže surfaktant i izborno fosfolipid, te
pri čemu jedna ili više od deformabilnih koloidnih čestica prve koloidne disperzije sadrži modificiranu komponentu koja sadrži prvi agens od interesa (AOI), pri čemu je modificirana komponenta lipid ili surfaktant kovalentno vezan za AOI, na način da je cijeli AOI izvan membrane čestice, te
pri čemu je prvi AOI cink.
2. Formulacija prema zahtjevu 1, pri čemu jedna ili više deformabilnih koloidnih čestica druge koloidne disperzije sadrži modificiranu komponentu koja sadrži drugi AOI i pri čemu su prvi AOI i drugi AOI različiti, pri čemu je svaka modificirana komponenta lipid ili surfaktant vezan za AOI.
3. Formulacija prema zahtjevu 1 ili zahtjevu 2, pri čemu jedna ili više deformabilnih koloidnih čestica prve koloidne disperzije i/ili jedna ili više deformabilnih koloidnih čestica druge koloidne disperzije sadrži modificirane komponente koje sadrže jedan ili više dodatnih AOI i pri čemu je svaki AOI različit, pri čemu je svaka modificirana komponenta lipid ili surfaktant vezan za AOI.
4. Formulacija prema zahtjevu 1, zahtjevu 2 ili zahtjevu 3, pri čemu formulacija sadrži jednu ili više dodatnih koloidnih disperzija koje sadrže deformabilne koloidne čestice koje sadrže surfaktant i izborno fosfolipid, i pri čemu jedna ili više čestica od barem dviju disperzija sadrži modificirane komponente koje sadrže jedan ili više AOI i pri čemu su prvi AOI, drugi AOI i svaki daljnji AOI različiti, pri čemu je modificirana komponenta lipid ili surfaktant vezan za AOI.
5. Formulacija prema bilo kojem od prethodnih zahtjeva, pri čemu čestica sadrži i komponentu modificiranog surfaktanta membrane vezikule i komponentu modificiranog lipida membrane vezikule.
6. Formulacija prema bilo kojem od prethodnih zahtjeva, pri čemu je drugi AOI odabran iz skupine koja se sastoji od elementa, iona, anorganske soli, male molekule, amino kiseline, peptida, proteina, ugljikohidrata, lipida, mikronutrijenta, makromolekule ili makrociklične molekule, izborno pri čemu drugi AOI i/ili svaki dodatni AOI je odabran od skupine koja se sastoji od cinka, askorbata, tetrapeptida, tripeptida, salicilne kiseline, vitamina D, tokoferola ili mentola.
7. Formulacija prema bilo kojem od prethodnih zahtjeva, pri čemu formulacija sadrži klorheksidin, salicilnu kiselinu, kapsaicin, kofein ili tokoferol, izborno pri čemu klorheksidin, salicilna kiselina, kapsaicin, kofein ili tokoferol nije povezan s deformabilnim koloidnim česticama.
8. Formulacija prema bilo kojem od prethodnih zahtjeva, pri čemu se formulacija primjenjuje lokalno.
9. Formulacija prema bilo kojem od prethodnih zahtjeva za uporabu u liječenju ili prevenciji bolesti.
10. Formulacija prema bilo kojem od prethodnih zahtjeva za uporabu u:
(i) liječenju ili prevenciji akni, ili
(ii) liječenju ili prevenciji suhe kože, svrbeža kože, crvene kože, iritirane kože, ljuskaste kože, kože koja stari, tanke kože, neujednačenog tena kože, periorbitalne kože, foto-ostarjele kože ili dermatitisa.
11. Formulacija prema bilo kojem od zahtjeva 1 do 8 za uporabu u njezi kože i/ili kozmetici.
12. Formulacija prema zahtjevu 11 za uporabu u poboljšavanju izgleda kože, pri čemu formulacija sadrži klorheksidin ili njegovu sol, izborno pri čemu pripravak poboljšava izgled kože jednim ili više od liječenja i prevencije akni, liječenja ili prevencije nastanka pjegi, mitesera i mrlja, smanjivanja nečistoća kože i sužavanja i smanjivanja pora u koži.
13. Formulacija prema zahtjevu 11 za uporabu u poboljšavanju izgleda neujednačenog tena kože, pri čemu formulacija sadrži salicilnu kiselinu ili njenu sol ili ester, izborno pri čemu formulacija dalje sadrži askorbinsku kiselinu i tokoferol ili njegov derivat, izborno pri čemu formulacija poboljšava izgled neujednačenog tena kože na jedan ili više od sljedećih načina; smanjivanje pojave bora, hiperpigmentacije, mrlja, tamnih podočnjaka, poboljšavanje izgleda teksture kože te povećanje elastičnosti kože.
14. Formulacija prema zahtjevu 11 za uporabu u poboljšavanju izgleda periorbitalne kože, pri čemu formulacija sadrži kofein, izborno pri čemu formulacija poboljšava izgled periorbitalne kože na jedan ili više od sljedećih načina; smanjivanje pojave bora, natečenosti očiju, vrećica donjeg kapka ili visećih i tamnih podočnjaka, poboljšavanje izgleda teksture kože te prevencija štete uzrokovane suncem.
15. Formulacija prema bilo kojem od zahtjeva 1 do 8 za kozmetičko obrađivanje subjekta.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1511478.8A GB201511478D0 (en) | 2015-06-30 | 2015-06-30 | Blended formulations |
| GBGB1511469.7A GB201511469D0 (en) | 2015-06-30 | 2015-06-30 | Compositions |
| PCT/EP2016/065415 WO2017001617A1 (en) | 2015-06-30 | 2016-06-30 | Blended formulations |
| EP16733592.6A EP3316856B1 (en) | 2015-06-30 | 2016-06-30 | Blended formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210903T1 true HRP20210903T1 (hr) | 2021-09-17 |
Family
ID=56292753
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211669TT HRP20211669T1 (hr) | 2015-06-30 | 2016-06-30 | Multifazni pripravci |
| HRP20210903TT HRP20210903T1 (hr) | 2015-06-30 | 2021-06-07 | Miješane formulacije |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211669TT HRP20211669T1 (hr) | 2015-06-30 | 2016-06-30 | Multifazni pripravci |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US20190167588A1 (hr) |
| EP (3) | EP3954361A1 (hr) |
| JP (2) | JP6851998B2 (hr) |
| CA (2) | CA3026484A1 (hr) |
| DK (2) | DK3316856T3 (hr) |
| EA (2) | EA038208B1 (hr) |
| ES (2) | ES2879383T3 (hr) |
| HK (2) | HK1254980A1 (hr) |
| HR (2) | HRP20211669T1 (hr) |
| HU (2) | HUE056161T2 (hr) |
| LT (2) | LT3316856T (hr) |
| MX (4) | MX2018000024A (hr) |
| PL (2) | PL3316856T3 (hr) |
| PT (2) | PT3316857T (hr) |
| WO (2) | WO2017001617A1 (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3954361A1 (en) | 2015-06-30 | 2022-02-16 | Sequessome Technology Holdings Limited | Multiphasic compositions |
| KR20180114911A (ko) | 2016-02-04 | 2018-10-19 | 앨러스틴 스킨케어, 인크. | 침습 및 비침습 시술적 피부 관리를 위한 조성물 및 방법 |
| KR20200036007A (ko) | 2017-08-03 | 2020-04-06 | 앨러스틴 스킨케어, 인크. | 피부 이완 및 신체 윤곽의 개선을 위한 조성물 및 방법 |
| US20190083386A1 (en) | 2017-09-15 | 2019-03-21 | Ampersand Biopharmaceuticals, Inc. | Methods and formulations for transdermal administration of buffering agents |
| US11103455B2 (en) | 2018-08-02 | 2021-08-31 | ALASTIN Skincare, Inc. | Liposomal compositions and methods of use |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4372296A (en) | 1980-11-26 | 1983-02-08 | Fahim Mostafa S | Treatment of acne and skin disorders and compositions therefor |
| JPS60136511A (ja) | 1983-12-26 | 1985-07-20 | Eisai Co Ltd | 高尿酸血症治療剤 |
| WO1987001938A1 (en) | 1985-09-27 | 1987-04-09 | The Regents Of The University Of California | Liposome transdermal drug delivery system |
| JPS6295134A (ja) | 1985-10-21 | 1987-05-01 | Nippon Saafuakutanto Kogyo Kk | リポソ−ムの製造法 |
| US5015483A (en) | 1989-02-09 | 1991-05-14 | Nabisco Brands, Inc. | Liposome composition for the stabilization of oxidizable substances |
| US5498607A (en) | 1990-07-30 | 1996-03-12 | University Of Miami | Treatment for hypercholesterolemia |
| US6165500A (en) | 1990-08-24 | 2000-12-26 | Idea Ag | Preparation for the application of agents in mini-droplets |
| JP3765579B2 (ja) | 1990-08-24 | 2006-04-12 | イーデーエーアー アーゲー | 作用物質投与用超微小滴状調剤 |
| US5498420A (en) | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
| EP0648114B1 (de) | 1992-07-08 | 1997-09-17 | DIANORM G. Maierhofer GmbH | Liposomen, verfahren zu ihrer herstellung und ihre verwendung zur herstellung eines arzneimittels |
| FR2714382B1 (fr) | 1993-12-27 | 1996-02-02 | Roussel Uclaf | Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques. |
| FR2714596B1 (fr) | 1993-12-30 | 1996-02-09 | Oreal | Composition cosmétique pour le traitement simultané des couches superficielles et profondes de la peau, son utilisation. |
| ATE205723T1 (de) | 1994-11-04 | 2001-10-15 | Polymun Scient Immunbio Forsch | Applikation von sod in liposomen |
| DE4447287C1 (de) | 1994-12-30 | 1996-11-07 | Cevc Gregor | Präparat zum Wirkstofftransport durch Barrieren |
| US5902604A (en) | 1995-06-06 | 1999-05-11 | Board Of Regents, The University Of Texas System | Submicron liposome suspensions obtained from preliposome lyophilizates |
| FR2767691B1 (fr) | 1997-08-27 | 2000-02-18 | Oreal | Utilisation d'une dispersion a base de vehicules lipidiques comme composition anti-inflammatoire |
| IL122084A (en) * | 1997-10-31 | 1999-09-22 | Lurident Ltd | Formulation for personal care with mucoadhesive properties |
| BR9814214B1 (pt) | 1997-11-19 | 2010-07-13 | composição com ácido azeláico. | |
| US6165997A (en) | 1997-11-20 | 2000-12-26 | Statens Serum Institut | Phospholipids having antimicrobial activity with or without the presence of antimicrobials |
| CA2283574A1 (en) * | 1998-01-16 | 1999-07-22 | Color Access, Inc. | Stabilized whitening compositions and method of preparing same |
| CN1322129A (zh) | 1998-09-01 | 2001-11-14 | 伊迪亚股份公司 | 带电穿透剂通过屏障的电控转运 |
| NZ332905A (en) | 1998-11-19 | 2000-12-22 | Immuno Lab Ltd | Transdermal pharmaceutical composition comprising liposomal bee venom |
| DE69825495T2 (de) | 1998-12-23 | 2005-07-28 | Idea Ag | Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo |
| ATE216875T1 (de) | 1999-01-27 | 2002-05-15 | Idea Ag | Nichtinvasive impfung durch die haut |
| GB9902527D0 (en) * | 1999-02-04 | 1999-03-24 | Phares Pharm Res Nv | Compositions |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| WO2001001962A1 (en) | 1999-07-05 | 2001-01-11 | Idea Ag. | A method for the improvement of transport across adaptable semi-permeable barriers |
| US6248728B1 (en) | 2000-03-10 | 2001-06-19 | Kansas State University Research Foundation | Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol |
| US6191121B1 (en) | 2000-04-06 | 2001-02-20 | Nicholas V. Perricone | Treatment of skin damage using polyenylphosphatidylcholine |
| ES2295149T3 (es) | 2000-04-12 | 2008-04-16 | Liplasome Pharma A/S | Sistemas de suministro de farmacos contra infecciones parasiticas. |
| TWI281407B (en) | 2000-09-18 | 2007-05-21 | Vasogen Ireland Ltd | Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| EP1230917A1 (de) | 2001-02-08 | 2002-08-14 | Vectron Therapeutics AG | Invasomen zur Therapie von Erkrankungen, ihre Herstellung und Verwendung |
| TNSN03127A1 (fr) | 2001-05-31 | 2005-12-23 | Pharmacia Corp | Composition d'inhibiteur de cyclo-oxygenase-2-selectif, apte a la penetration dermique |
| WO2003000190A2 (en) | 2001-06-25 | 2003-01-03 | Depuy | Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints |
| CA2368656A1 (en) | 2002-01-21 | 2003-07-21 | Vasogen Ireland Limited | Receptor-ligand pairing for anti-inflammatory response |
| EP1534213B1 (en) | 2002-03-13 | 2013-04-24 | Sköld, Thomas | Water-based delivery systems |
| US8119168B2 (en) * | 2002-04-22 | 2012-02-21 | The Procter & Gamble Company | Personal care compositions comprising a zinc containing material in an aqueous surfactant composition |
| US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
| WO2004032900A1 (en) | 2002-10-11 | 2004-04-22 | Idea Ag | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| US7473432B2 (en) | 2002-10-11 | 2009-01-06 | Idea Ag | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery |
| JP2004131432A (ja) | 2002-10-11 | 2004-04-30 | Kumamoto Technology & Industry Foundation | 悪性腫瘍抑制剤 |
| WO2004098524A2 (en) | 2003-05-02 | 2004-11-18 | Aronex Pharmaceuticals, Inc. | Lipid platinum complexes and methods of use thereof |
| EP1514539A3 (en) * | 2003-05-14 | 2005-05-04 | Signal Investment & Management Co. | Micro-encapsulated topical analgesic for pain relief and sleeve comprising it |
| CN1826123A (zh) | 2003-07-21 | 2006-08-30 | 瓦索金爱尔兰有限公司 | 急性炎症状态的治疗方法 |
| JP2005179313A (ja) | 2003-12-24 | 2005-07-07 | Shu Uemura:Kk | 皮膚化粧料用基剤の製造方法および皮膚化粧料 |
| US7476432B2 (en) | 2004-05-28 | 2009-01-13 | Tecton Products | Phosphorescent pultrusion |
| KR20070086045A (ko) | 2004-11-12 | 2007-08-27 | 이데아 아게 | 피부 상태 치료에서의 확대된 표면 집합체 |
| WO2006086992A2 (en) | 2005-02-18 | 2006-08-24 | Liplasome Pharma A/S | Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands |
| US20070042008A1 (en) | 2005-08-18 | 2007-02-22 | Bodybio, Inc. | Compositions containing phosphatidylcholine and essential fatty acids |
| AU2006284990B2 (en) | 2005-08-29 | 2011-01-06 | Sepsicure L.L.C. | Method for treatment or prevention of conditions caused by gram-positive bacteria |
| TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
| WO2007075841A1 (en) | 2005-12-20 | 2007-07-05 | Cenestra, Llc | Omega 3 fatty acid formulations |
| JP5009547B2 (ja) | 2006-03-31 | 2012-08-22 | 株式会社コーセー | 顔料とリポソームを含む化粧料 |
| US7544375B1 (en) | 2006-06-12 | 2009-06-09 | Swiss Skin Repair, Inc. | Composition |
| US20080131497A1 (en) * | 2006-09-28 | 2008-06-05 | Perkins Walter R | Formulations of DNase and Methods of Use Thereof |
| JP5660561B2 (ja) | 2006-09-28 | 2015-01-28 | ハダシット メディカルリサーチサービセス アンド ディベロップメント リミテッド | ジョイント部の潤滑に関するグリセロリン脂質の使用 |
| JP4732307B2 (ja) | 2006-11-20 | 2011-07-27 | 株式会社アンズコーポレーション | ナノエマルション及びそれを配合した化粧料 |
| US20100130611A1 (en) | 2006-12-20 | 2010-05-27 | Cenestra Llc | Omega 3 fatty acid formulations |
| EP1938801A1 (en) | 2006-12-22 | 2008-07-02 | Biofrontera Bioscience GmbH | Nanoemulsion |
| US9511016B2 (en) | 2007-06-12 | 2016-12-06 | Epicentrx, Inc. | Topical composition for treating pain |
| ITVR20080006A1 (it) | 2008-01-23 | 2009-07-24 | David Ceretta | Apparato per la realizzazione di elementi d'impasto |
| ES2335636B1 (es) | 2008-02-29 | 2011-05-11 | Lipotec, S.A. | Composicion cosmetica o dermofarmaceutica de micelas mixtas. |
| JP2009256331A (ja) | 2008-03-25 | 2009-11-05 | Nagase Chemtex Corp | 高尿酸血症、又は痛風の予防、改善、又は治療剤 |
| US20100105139A1 (en) | 2008-10-27 | 2010-04-29 | Remco Alexander Spanjaard | Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents |
| US20100197621A1 (en) | 2009-02-05 | 2010-08-05 | William Henry | Methods of reducing the proliferation and viability of microbial agents |
| EA029132B1 (ru) | 2009-06-03 | 2018-02-28 | Секвессам Текнолоджи Холдингс Лимитед | Составы в виде везикул для лечения боли, связанной с остеоартритом |
| NZ598906A (en) | 2009-08-21 | 2014-08-29 | Targeted Delivery Technologies Ltd | Vesicular formulations |
| EP2382994A1 (en) | 2010-04-26 | 2011-11-02 | Maurizio Victor Cattaneo | Ligand targeted nanocapsules for the delivery of RNAi and other agents |
| US8741373B2 (en) | 2010-06-21 | 2014-06-03 | Virun, Inc. | Compositions containing non-polar compounds |
| US20120045405A1 (en) | 2010-08-18 | 2012-02-23 | Gilman Miles E | Under eye cream |
| US20120294924A1 (en) | 2011-04-29 | 2012-11-22 | Thomas Tice | Peptide-Lipid Conjugates And Uses Thereof |
| GB201205642D0 (en) | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
| GB201206486D0 (en) | 2012-04-12 | 2012-05-30 | Sequessome Technology Holdings Ltd | Vesicular formulations and uses thereof |
| GB201208384D0 (en) | 2012-05-14 | 2012-06-27 | Sequessome Technology Holdings Ltd | Vesicular formulations, uses and methods |
| GB201208409D0 (en) | 2012-05-14 | 2012-06-27 | Sequessome Technology Holdings Ltd | Vesicular formulations, kits and uses |
| CN114949237A (zh) * | 2013-07-31 | 2022-08-30 | 斯昆申技术控股有限责任公司 | 囊泡 |
| EP3954361A1 (en) | 2015-06-30 | 2022-02-16 | Sequessome Technology Holdings Limited | Multiphasic compositions |
| WO2020247683A1 (en) * | 2019-06-04 | 2020-12-10 | Aquavit Pharmaceuticals, Inc. | Methods and compositions for microflillng the skin with hyaluronic acid using microchannel technology |
-
2016
- 2016-06-30 EP EP21189470.4A patent/EP3954361A1/en active Pending
- 2016-06-30 WO PCT/EP2016/065415 patent/WO2017001617A1/en active Application Filing
- 2016-06-30 HU HUE16733595A patent/HUE056161T2/hu unknown
- 2016-06-30 CA CA3026484A patent/CA3026484A1/en active Pending
- 2016-06-30 EP EP16733592.6A patent/EP3316856B1/en active Active
- 2016-06-30 PT PT167335959T patent/PT3316857T/pt unknown
- 2016-06-30 MX MX2018000024A patent/MX2018000024A/es unknown
- 2016-06-30 EA EA201890120A patent/EA038208B1/ru unknown
- 2016-06-30 ES ES16733592T patent/ES2879383T3/es active Active
- 2016-06-30 US US15/739,570 patent/US20190167588A1/en not_active Abandoned
- 2016-06-30 HR HRP20211669TT patent/HRP20211669T1/hr unknown
- 2016-06-30 DK DK16733592.6T patent/DK3316856T3/da active
- 2016-06-30 LT LTEP16733592.6T patent/LT3316856T/lt unknown
- 2016-06-30 EA EA201890119A patent/EA038613B1/ru unknown
- 2016-06-30 HU HUE16733592A patent/HUE054749T2/hu unknown
- 2016-06-30 LT LTEPPCT/EP2016/065425T patent/LT3316857T/lt unknown
- 2016-06-30 EP EP16733595.9A patent/EP3316857B1/en active Active
- 2016-06-30 WO PCT/EP2016/065425 patent/WO2017001625A1/en active Application Filing
- 2016-06-30 DK DK16733595.9T patent/DK3316857T3/da active
- 2016-06-30 ES ES16733595T patent/ES2895910T3/es active Active
- 2016-06-30 MX MX2021004766A patent/MX2021004766A/es unknown
- 2016-06-30 PT PT167335926T patent/PT3316856T/pt unknown
- 2016-06-30 PL PL16733592T patent/PL3316856T3/pl unknown
- 2016-06-30 MX MX2018000021A patent/MX2018000021A/es unknown
- 2016-06-30 US US15/739,575 patent/US10744090B2/en active Active
- 2016-06-30 PL PL16733595T patent/PL3316857T3/pl unknown
- 2016-06-30 JP JP2017568160A patent/JP6851998B2/ja active Active
- 2016-06-30 CA CA3026466A patent/CA3026466A1/en active Pending
-
2017
- 2017-12-20 MX MX2021003510A patent/MX2021003510A/es unknown
-
2018
- 2018-11-05 HK HK18114089.3A patent/HK1254980A1/zh unknown
- 2018-11-05 HK HK18114088.4A patent/HK1254979A1/zh unknown
-
2020
- 2020-07-08 US US16/923,810 patent/US20220370353A9/en not_active Abandoned
- 2020-07-14 US US16/929,009 patent/US11547665B2/en active Active
-
2021
- 2021-03-10 JP JP2021038221A patent/JP2021091730A/ja active Pending
- 2021-06-07 HR HRP20210903TT patent/HRP20210903T1/hr unknown
-
2023
- 2023-10-19 US US18/490,255 patent/US20240099976A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210903T1 (hr) | Miješane formulacije | |
| US11234921B2 (en) | Moisturizing compositions and uses thereof | |
| US11052032B2 (en) | Peptide compositions and methods for ameliorating skin laxity and body contour | |
| KR102448943B1 (ko) | 슈도알테로모나스 앤타륵티카로부터의 박테리아 세포외 생성물을 함유하는 미용적 및/또는 약학적 조성물, 및 이의 용도 | |
| AU2010257247B2 (en) | Mild leave-on skin care compositions | |
| ES2820304T3 (es) | Formulaciones de finasterida para la liberación de fármacos en el cabello y el cuero cabelludo | |
| ES2659453T3 (es) | Composiciones tópicas que comprenden Pichia anomala y extractos de raíces de achicoria | |
| ES2335636B1 (es) | Composicion cosmetica o dermofarmaceutica de micelas mixtas. | |
| JP5180556B2 (ja) | ユビキノン誘導体またはその塩を含む皮膚外用剤および化粧料ならびにこれらの使用方法 | |
| EP2218447A1 (en) | Compositions containing lipid micro- or nanoparticles for the enhancement of the dermal action of solid particles | |
| CN103099800B (zh) | 含有氨甲环酸的外用和内服用组合物 | |
| KR20140008299A (ko) | 화장용 피부 관리 조성물 | |
| US9211238B2 (en) | Carrier system for the transport of active substances into the skin | |
| ES2903108T3 (es) | Composiciones y métodos de estimulación de células madre | |
| GB2458228A (en) | External preparation for skin | |
| JP4088436B2 (ja) | 皮膚外用剤 | |
| WO2016187012A1 (en) | Formulations for treatment of skin and methods of making and using the same | |
| JP2015110550A (ja) | 拭き取りシート | |
| CN102176894A (zh) | 油光控制清洁剂 | |
| Aparajita et al. | Liposomes as carriers in skin ageing | |
| WO2015184347A1 (en) | Methods and compositions for the use of silver to prevent and treat acne | |
| JP2019137695A (ja) | 皮膚有効成分の浸透方法 | |
| JP2021520371A (ja) | 表皮の処置を目的とするペプチドの使用 | |
| JP6963137B1 (ja) | 天然保湿因子を利用して形成されたミセル複合体を含む化粧料組成物の製造方法、ならびに該製造方法によって製造された化粧料組成物 | |
| JP2004083503A (ja) | 皮膚外用剤 |